{"id":745359,"date":"2016-06-13T09:30:00","date_gmt":"2016-06-13T09:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\/"},"modified":"2025-11-07T01:25:47","modified_gmt":"2025-11-07T06:25:47","slug":"mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\/","title":{"rendered":"Merck\u2019s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus\u00ae"},"content":{"rendered":"<p class=\"bwalignc\">       Data in Patients with Type 1 and Type 2 Diabetes Presented for the        First Time at the 76 <sup> th <\/sup>  Scientific Sessions of        the American Diabetes Association     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced results from two Phase 3 studies evaluating MK-1293,<br \/>\n      Merck\u2019s investigational, follow-on biologic* insulin glargine candidate<br \/>\n      for the treatment of people with type 1 and type 2 diabetes. In both<br \/>\n      studies, MK-1293 achieved its primary endpoint by demonstrating<br \/>\n      non-inferiority in change from baseline A1C (a measure of average blood<br \/>\n      glucose) and similar safety to Lantus<sup>\u00ae <\/sup>(insulin glargine)**<br \/>\n      after 24 weeks in patients with type 1 and type 2 diabetes. Furthermore,<br \/>\n      in both studies, MK-1293 met its pre-specified secondary efficacy<br \/>\n      endpoints of statistical A1C equivalence to Lantus, a measure used to<br \/>\n      show that an investigational treatment is similar, within an acceptable<br \/>\n      range, to a current therapy.\n    <\/p>\n<p>\n      \u201cIt is encouraging to see that the investigational agent MK-1293 met its<br \/>\n      primary and secondary endpoints,\u201d said Philip Home, D.M., D.Phil,<br \/>\n      professor of diabetes medicine, Newcastle University, United Kingdom.<br \/>\n      \u201cThese data, together with other clinical studies of its time-action<br \/>\n      profile, suggest that Merck\u2019s insulin glargine, if approved, could help<br \/>\n      provide glycemic control in appropriate patients with type 1 and type 2<br \/>\n      diabetes.\u201d\n    <\/p>\n<p>\n      MK-1293 has the same amino acid sequence as Lantus, the originator<br \/>\n      insulin glargine. The development of MK-1293 builds on an agreement<br \/>\n      between Merck and Samsung Bioepis established in February 2013 to<br \/>\n      develop and commercialize multiple biosimilar candidates across<br \/>\n      different therapeutic areas. Under the terms of a subsequent 2014<br \/>\n      agreement, Merck is responsible for the clinical development,<br \/>\n      manufacturing and, if approved, commercialization of MK-1293. Samsung<br \/>\n      Bioepis is partially funding its development.\n    <\/p>\n<p>\n      \u201cThe investigational agent MK-1293 represents Merck\u2019s entry into insulin<br \/>\n      therapeutics and into treatments that may be useful for patients with<br \/>\n      type 1 diabetes, and we are pleased with these Phase 3 results,\u201d said<br \/>\n      Peter Stein, M.D., vice president, late stage development, diabetes and<br \/>\n      endocrinology, Merck. \u201cAs a follow-on biologic, MK-1293 has the<br \/>\n      potential to offer a treatment option for pediatric and adult patients<br \/>\n      with type 1 diabetes and for adults with type 2 diabetes who use basal<br \/>\n      insulin to help control their glucose levels.\u201d\n    <\/p>\n<p>\n      <b>MK-1293 in Patients with Type 1 Diabetes (296-OR)<\/b>\n    <\/p>\n<p>\n      The Phase 3, randomized, active-controlled, open-label trial assessed<br \/>\n      the efficacy and safety of MK-1293 (n= 245) compared with Lantus (n=263)<br \/>\n      in patients with type 1 diabetes. The primary efficacy endpoint was<br \/>\n      non-inferiority of change from baseline A1C at week 24. At baseline,<br \/>\n      patients had an A1C level equal to or less than 11.0 percent and were<br \/>\n      taking basal and prandial insulin.\n    <\/p>\n<p>\n      The primary endpoint of the study was met, demonstrating the<br \/>\n      non-inferiority of MK-1293 to Lantus in patients with type 1 diabetes.<br \/>\n      The least-squares mean difference in A1C (MK-1293 minus Lantus) was 0.04<br \/>\n      percent (95% CI: -0.11, 0.19), meeting A1C non-inferiority (upper bound<br \/>\n      of the confidence interval &lt;0.4%) and equivalence (confidence interval<br \/>\n      within -0.4% and 0.4%) criteria. Basal insulin doses were similar<br \/>\n      between groups (MK-1293 minus Lantus; difference of -0.7 U\/day; 95% CI<br \/>\n      -2.5, 1.0 U\/day).\n    <\/p>\n<p>\n      The primary safety objective was anti-insulin antibody (AIA)<br \/>\n      development. Similar AIA, including incidence and titers, and similar<br \/>\n      neutralizing antibody responses were seen between treatment groups. The<br \/>\n      study found that 74 percent of patients receiving Lantus and 70 percent<br \/>\n      receiving MK-1293, irrespective of AIA status at baseline, had an AIA<br \/>\n      positive result at or before week 24. Additionally, 36 percent of<br \/>\n      patients receiving Lantus and 33 percent of patients receiving MK-1293<br \/>\n      who were negative for AIA at baseline had an AIA positive result at or<br \/>\n      before week 24.\n    <\/p>\n<p>\n      No clinically meaningful difference in safety endpoints of interest were<br \/>\n      seen between treatment groups. In this study, 76.4 percent of patients<br \/>\n      receiving Lantus and 71.0 percent of patients receiving MK-1293<br \/>\n      experienced symptomatic hypoglycemia. In addition, 0.4 percent of<br \/>\n      patients receiving Lantus and 0.8 percent of patients receiving MK-1293<br \/>\n      experienced an injection site reaction; 0.4 percent of patients<br \/>\n      receiving MK-1293 and none taking Lantus experienced a systemic allergic<br \/>\n      reaction; 1.9 percent of patients receiving Lantus and 0.4 percent of<br \/>\n      patients receiving MK-1293 experienced angioedema or a severe cutaneous<br \/>\n      adverse reaction. There were no reports of anaphylactic response in<br \/>\n      either treatment group.\n    <\/p>\n<p>\n      <b>MK-1293 in Patients with Type 2 Diabetes (926-P)<\/b>\n    <\/p>\n<p>\n      The Phase 3, randomized, active-controlled, open-label trial assessed<br \/>\n      the efficacy and safety of MK-1293 (n=265) compared to Lantus (n=266) in<br \/>\n      patients with type 2 diabetes inadequately controlled on diet and<br \/>\n      exercise alone. The primary efficacy endpoint was non-inferiority of<br \/>\n      change from baseline A1C at week 24. At baseline, patients had an A1C<br \/>\n      level equal to or less than 11.0 percent and were eligible for or were<br \/>\n      taking basal insulin greater than or equal to 10 U\/day.\n    <\/p>\n<p>\n      MK-1293 met the study\u2019s primary endpoint, demonstrating non-inferiority<br \/>\n      to Lantus with a least-squares mean difference in A1C (MK-1293 minus<br \/>\n      Lantus) of 0.03 percent (95% CI: -0.12, 0.18), meeting A1C<br \/>\n      non-inferiority (upper bound of the confidence interval &lt;0.4%) and<br \/>\n      equivalence (confidence interval within -0.4% and 0.4%) criteria. Basal<br \/>\n      insulin doses were similar between groups (MK-1293 minus Lantus;<br \/>\n      difference of 1.4 U\/day; 95% CI -2.2, 4.9 U\/day).\n    <\/p>\n<p>\n      The primary safety objective was anti-insulin antibody (AIA)<br \/>\n      development. Similar AIA, including incidence and titers, and similar<br \/>\n      neutralizing antibody responses were seen between treatment groups. In<br \/>\n      the study, 29.0 percent of patients receiving Lantus and 34.7 percent<br \/>\n      being treated with MK-1293, irrespective of AIA status at baseline, had<br \/>\n      an AIA positive at or before week 24. Additionally, 14.9 percent of<br \/>\n      patients receiving Lantus and 19.3 percent of patients receiving MK-1293<br \/>\n      who were negative of AIA at baseline had an AIA positive at or before<br \/>\n      week 24.\n    <\/p>\n<p>\n      No clinically meaningful between-group differences were found for<br \/>\n      pre-defined safety endpoints of interest. Symptomatic hypoglycemia was<br \/>\n      observed in 52.1 percent of patients receiving Lantus and 53.2 percent<br \/>\n      of patients receiving MK-1293. In the study, 0.4 percent of patients<br \/>\n      receiving Lantus and 1.9 percent of patients receiving MK-1293<br \/>\n      experienced an injection site reaction; 0.4 percent of patients<br \/>\n      receiving MK-1293 and none taking Lantus experienced a systemic allergic<br \/>\n      reaction; 0.4 percent of patients receiving MK-1293 and none taking<br \/>\n      Lantus experienced an anaphylactic response; and 1.1 percent of patients<br \/>\n      receiving Lantus and 0.4 percent of patients receiving MK-1293<br \/>\n      experienced angioedema or severe cutaneous adverse reaction.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51361033&amp;newsitemid=20160613005707&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=748c5c3dac43210e8cb38ee5c3c033b3\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51361033&amp;newsitemid=20160613005707&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=4d62078ceba12cd51d48866f2a85a519\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51361033&amp;newsitemid=20160613005707&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=bb8a46eaef6d2295a114477e99040cfa\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51361033&amp;newsitemid=20160613005707&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=76b69c7d9b85cb9ab6ffa78222f48610\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51361033&amp;newsitemid=20160613005707&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=0bdd790145dd07d350a755f74d66ea2b\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51361033&amp;newsitemid=20160613005707&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=6eecb1474de40567c1a660f9fb8e6b71\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      *A follow-on biologic is a similar, but not identical, version of an<br \/>\n      approved reference product. In the U.S., MK-1293 is referred to as a<br \/>\n      follow-on biologic because of its regulatory pathway. In other<br \/>\n      countries, it is considered to be a biosimilar.\n    <\/p>\n<p>\n      **LANTUS is a registered trademark of Sanofi-Aventis, which is not<br \/>\n      affiliated with the maker of MK-1293 and does not endorse MK-1293.\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160613005707r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-246-5701<br \/>Kristen Drake,        908-334-4688<br \/>or<br \/>Investor:<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Merck\u2019s investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. In both studies, MK-1293 achieved its primary endpoint by demonstrating non-inferiority in change from baseline A1C (a measure of average blood glucose) and similar safety to Lantus\u00ae (insulin glargine)** after 24 weeks in patients with type 1 and type 2 diabetes. Furthermore, in both studies, MK-1293 met its pre-specified secondary efficacy endpoints of statistical A1C equivalence to Lantus, a measure used to show that an investigational treatment is similar, within an acceptable range, to a current therapy. \u201cIt is encouraging to see that the investigational agent<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745359","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus\u00ae - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus\u00ae - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Merck\u2019s investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. In both studies, MK-1293 achieved its primary endpoint by demonstrating non-inferiority in change from baseline A1C (a measure of average blood glucose) and similar safety to Lantus\u00ae (insulin glargine)** after 24 weeks in patients with type 1 and type 2 diabetes. Furthermore, in both studies, MK-1293 met its pre-specified secondary efficacy endpoints of statistical A1C equivalence to Lantus, a measure used to show that an investigational treatment is similar, within an acceptable range, to a current therapy. \u201cIt is encouraging to see that the investigational agent\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\\\/\",\"name\":\"Merck\u2019s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus\u00ae - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-06-13T09:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus\u00ae - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus\u00ae - Merck.com","og_description":"Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Merck\u2019s investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. In both studies, MK-1293 achieved its primary endpoint by demonstrating non-inferiority in change from baseline A1C (a measure of average blood glucose) and similar safety to Lantus\u00ae (insulin glargine)** after 24 weeks in patients with type 1 and type 2 diabetes. Furthermore, in both studies, MK-1293 met its pre-specified secondary efficacy endpoints of statistical A1C equivalence to Lantus, a measure used to show that an investigational treatment is similar, within an acceptable range, to a current therapy. \u201cIt is encouraging to see that the investigational agent","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:47+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\/","name":"Merck\u2019s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus\u00ae - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-06-13T09:30:00+00:00","dateModified":"2025-11-07T06:25:47+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-investigational-insulin-glargine-mk-1293-met-primary-endpoint-in-two-phase-3-studies-showing-non-inferiority-to-lantus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f8a302c9-d133-4e80-994a-307394c6fa62","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-Investigational-Insulin-Glargine-MK-1293-Met-Primary-Endpoint-in-Two-Phase-3-Studies-Showing-Non-Inferiority-to-Lantus-2016.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745359\/revisions"}],"predecessor-version":[{"id":3674761,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745359\/revisions\/3674761"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745359"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}